Effectiveness of recombinant human erythropoietin injection in patients undergoing total hip/knee arthroplasty: a randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022155

Enrollment

Unknown

Registered

2019-03-27

Start date

2019-03-28

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-staged joint diseases

Interventions

A:Control

B:Epoetin-a + Oral iron preoperatively

C:Epoetin-a + Oral iron preoperatively,Epoetin-a + Oral iron postoperatively

D:Epoetin-a + Oral iron preoperatively,Epoetin-a + intravenous iron postoperatively

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients receiving total hip arthroplasty/total knee arthroplasty for end-staged joint diseases; 2. Aged 20-70 years with no limitation of gender; 3. For male, the preoperative Hb should be 110-130g/L. For female, the preoperative Hb should be 110-130 g/L; 4. Patients who volunteered to participate in clinical trials and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients combined with acute trauma, tumor, severe osteoporosis, other autoimmune diseases and severe muscle contracture deformity around hip/knee; 2. Previous history of neuro-vascular injury, vasculitis and diabetic foot etc; 3. Related thrombosis history, such as pulmonary embolism, thrombosis and deep vein thrombosis in recent three months; 4. Coagulation disorders, bleeding tendency or intraoperative active bleeding; 5. Clear history of iron metabolism disorders; 6. Sever comorbidities in brain cardiovascular system, liver (ALT or AST >2 high limitation of normal value), kidney (BUN >1.5 high limitation of normal value or Cr> 1.5 high limitation of normal value), endocrine, nerve, hematopoietic system or consciousness disorders; 7. Pregnancy or breast-feeding; 8. Allergy to the test drug and human serum albumin, severe allergies, drug or alcohol depedence; 9. Participate in other clinical trials in recent three months; 10. The surgeons believe the patients not suitable for this clinical trial.

Design outcomes

Primary

Measure	Time frame
Hb;	—

Secondary

Measure	Time frame
Hct;PLT;ESR;CRP;Coagulation index;Ferritin, serum iron, total iron binding, reticulocytes, transferrin saturation;DVT;Complications;	—

Countries

China

Contacts

Public ContactZhou Zongke

West China Hospital, Sichuan University

zongke@126.com+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026